secwatch.observer — SEC 8-K summary
======================================

Issuer:     Corbus Pharmaceuticals Holdings, Inc. (CRBP)
CIK:        0001595097
Form:       8-K
Filed at:   2026-09-14T11:06:27+00:00
Accession:  0001193125-26-389829
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Corbus CANYON-1: CRB-913 hits 5% mean weight loss at 60 mg; all doses p<0.0001
------------------------------------------------------------------------------

- Phase 1b CANYON-1 (NCT07310901): 254 obese adults, 16-week trial; LS mean weight loss vs placebo: 2.8% (20 mg), 3.3% (40 mg), 5.0% (60 mg) at week 12, all p<0.0001.
- Safety: no serious psychiatric AEs, no suicidality; GI AEs milder than oral GLP-1s (vomiting 1.6-8.2% vs 31% for semaglutide 25 mg).
- Discontinuation rate due to AEs 3.1%-13.1%, markedly lower than monlunabant's 13%-42%.
- Data selected for late-breaking presentation at ObesityWeek 2026 (Nov 14-17, 2026).
- Plans FDA engagement and Phase 2 monotherapy start in 1H 2027; evaluating combo with GLP-1 therapy.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1595097/000119312526389829/0001193125-26-389829-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1595097/000119312526389829/crbp-20260914.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-389829

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer